PURPOSE: To establish the performance characteristics of annual transvaginal ultrasound and serum CA125 screening for women at high risk of ovarian/fallopian tube cancer (OC/FTC) and to investigate the impact of delayed screening interval and surgical intervention. PATIENTS AND METHODS: Between May 6, 2002, and January 5, 2008, 3,563 women at an estimated ≥ 10% lifetime risk of OC/FTC were recruited and screened by 37 centers in the United Kingdom. Participants were observed prospectively by centers, questionnaire, and national cancer registries. RESULTS: Sensitivity for detection of incident OC/FTC at 1 year after last annual screen was 81.3% (95% CI, 54.3% to 96.0%) if occult cancers were classified as false negatives and 87.5% (95% CI, 61.7% to 98.5%) if they were classified as true positives. Positive and negative predictive values of incident screening were 25.5% (95% CI, 14.3 to 40.0) and 99.9% (95% CI, 99.8 to 100) respectively. Four (30.8%) of 13 incident screen-detected OC/FTCs were stage I or II. Compared with women screened in the year before diagnosis, those not screened in the year before diagnosis were more likely to have ≥ stage IIIc disease (85.7% v 26.1%; P = .009). Screening interval was delayed by a median of 88 days before detection of incident OC/FTC. Median interval from detection screen to surgical intervention was 79 days in prevalent and incident OC/FTC. CONCLUSION: These results in the high-risk population highlight the need for strict adherence to screening schedule. Screening more frequently than annually with prompt surgical intervention seems to offer a better chance of early-stage detection.
PURPOSE: To establish the performance characteristics of annual transvaginal ultrasound and serum CA125 screening for women at high risk of ovarian/fallopian tube cancer (OC/FTC) and to investigate the impact of delayed screening interval and surgical intervention. PATIENTS AND METHODS: Between May 6, 2002, and January 5, 2008, 3,563 women at an estimated ≥ 10% lifetime risk of OC/FTC were recruited and screened by 37 centers in the United Kingdom. Participants were observed prospectively by centers, questionnaire, and national cancer registries. RESULTS: Sensitivity for detection of incident OC/FTC at 1 year after last annual screen was 81.3% (95% CI, 54.3% to 96.0%) if occult cancers were classified as false negatives and 87.5% (95% CI, 61.7% to 98.5%) if they were classified as true positives. Positive and negative predictive values of incident screening were 25.5% (95% CI, 14.3 to 40.0) and 99.9% (95% CI, 99.8 to 100) respectively. Four (30.8%) of 13 incident screen-detected OC/FTCs were stage I or II. Compared with women screened in the year before diagnosis, those not screened in the year before diagnosis were more likely to have ≥ stage IIIc disease (85.7% v 26.1%; P = .009). Screening interval was delayed by a median of 88 days before detection of incident OC/FTC. Median interval from detection screen to surgical intervention was 79 days in prevalent and incident OC/FTC. CONCLUSION: These results in the high-risk population highlight the need for strict adherence to screening schedule. Screening more frequently than annually with prompt surgical intervention seems to offer a better chance of early-stage detection.
Authors: A Dørum; K Heimdal; K Løvslett; G Kristensen; L J Hansen; R Sandvei; A Schiefloe; B Hagen; A Himmelmann; F Jerve; K Shetelig; I Fjaerestad; C Tropé; P Møller Journal: Acta Obstet Gynecol Scand Date: 1999-11 Impact factor: 3.636
Authors: H A Risch; J R McLaughlin; D E Cole; B Rosen; L Bradley; E Kwan; E Jack; D J Vesprini; G Kuperstein; J L Abrahamson; I Fan; B Wong; S A Narod Journal: Am J Hum Genet Date: 2001-02-15 Impact factor: 11.025
Authors: H F Vasen; A Stormorken; F H Menko; F M Nagengast; J H Kleibeuker; G Griffioen; B G Taal; P Moller; J T Wijnen Journal: J Clin Oncol Date: 2001-10-15 Impact factor: 44.544
Authors: Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs Journal: Lancet Oncol Date: 2009-03-11 Impact factor: 41.316
Authors: D G Evans; K N Gaarenstroom; D Stirling; A Shenton; L Maehle; A Dørum; M Steel; F Lalloo; J Apold; M E Porteous; H F A Vasen; C J van Asperen; P Moller Journal: J Med Genet Date: 2008-04-15 Impact factor: 6.318
Authors: Steven J Skates; Mark H Greene; Saundra S Buys; Phuong L Mai; Powel Brown; Marion Piedmonte; Gustavo Rodriguez; John O Schorge; Mark Sherman; Mary B Daly; Thomas Rutherford; Wendy R Brewster; David M O'Malley; Edward Partridge; John Boggess; Charles W Drescher; Claudine Isaacs; Andrew Berchuck; Susan Domchek; Susan A Davidson; Robert Edwards; Steven A Elg; Katie Wakeley; Kelly-Anne Phillips; Deborah Armstrong; Ira Horowitz; Carol J Fabian; Joan Walker; Patrick M Sluss; William Welch; Lori Minasian; Nora K Horick; Carol H Kasten; Susan Nayfield; David Alberts; Dianne M Finkelstein; Karen H Lu Journal: Clin Cancer Res Date: 2017-01-31 Impact factor: 12.531
Authors: Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Sheri D Schully; Danielle M Carrick; Leah E Mechanic; Sudhir Srivastava; Garnet L Anderson; John A Baron; Christine D Berg; Jennifer Cullen; Eleftherios P Diamandis; V Paul Doria-Rose; Katrina A B Goddard; Susan E Hankinson; Lawrence H Kushi; Eric B Larson; Lisa M McShane; Richard L Schilsky; Steven Shak; Steven J Skates; Nicole Urban; Barnett S Kramer; Muin J Khoury; David F Ransohoff Journal: J Natl Cancer Inst Date: 2015-02-16 Impact factor: 13.506
Authors: Ying Chen; Elizabeth Bancroft; Sue Ashley; Audrey Arden-Jones; Sarah Thomas; Susan Shanley; Sibel Saya; Emma Wakeling; Rosalind Eeles Journal: Fam Cancer Date: 2014-06 Impact factor: 2.375
Authors: Beth Y Karlan; Jason Thorpe; Kate Watabayashi; Charles W Drescher; Melanie Palomares; Mary B Daly; Pam Paley; Paula Hillard; M Robyn Andersen; Garnet Anderson; Ronny Drapkin; Nicole Urban Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-01 Impact factor: 4.254
Authors: Basil H Shadfan; Archana R Simmons; Glennon W Simmons; Andy Ho; Jorge Wong; Karen H Lu; Robert C Bast; John T McDevitt Journal: Cancer Prev Res (Phila) Date: 2014-11-11